<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24996">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819714</url>
  </required_header>
  <id_info>
    <org_study_id>PHRIP/2012/JD</org_study_id>
    <secondary_id>2013-A00005-40</secondary_id>
    <nct_id>NCT01819714</nct_id>
  </id_info>
  <brief_title>Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease</brief_title>
  <acronym>SensiCare</acronym>
  <official_title>Evaluation of the Impact of Care Based on Sensory Support for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the effect of 3 months of &quot;Snoezelen-type&quot;
      multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for
      patients with Alzheimer's-type neurodegenerative disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are to study the following elements in relationship
      to the implementation of a &quot;Snoezelen-type&quot; multi-sensory care strategy for patients with
      Alzheimer's-type neurodegenerative disease:

      A. to evaluate the effects  on NPI-Q scores at 1 month, 6 months and 12 months .

      B. evaluate the effects on quality of life (questionnaire QOL-AD) at 0 and 12 months.

      C. assess changes in the &quot;aggressive behavior&quot;  subsection of the Cohen-Mansfield Agitation
      Inventory (CMAI) questionnaire over 0, 1, 3, 6 and 12 months.

      D. assess changes in drug consumption (anxiolytics, antidepressants, hypnotics,
      neuroleptics)over the study period
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change from baseline in NPI-Q scores</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NPI-Q scores</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NPI-Q scores</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NPI-Q scores</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the &quot;aggressive behavior&quot; subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the &quot;aggressive behavior&quot; subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the &quot;aggressive behavior&quot; subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the &quot;aggressive behavior&quot; subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug consumption from baseline</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug consumption from baseline</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug consumption from baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drug consumption from baseline</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multi-sensory supportive care</intervention_name>
    <description>The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.
The impact of this multisensory strategy will be evaluated using a before-after design.</description>
    <arm_group_label>Study population</arm_group_label>
    <other_name>Snoezelen-type care</other_name>
    <other_name>Snoezelen toilette</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient's legal representative must have given his/her informed and signed
             consent (or the patient if he/she is judged competent)

          -  The patient must be insured or beneficiary of a health insurance plan

          -  Alzheimer's-type neurodegenerative pathology

          -  The patient has been living in the participating center for &gt; 2 months

        Exclusion Criteria:

          -  The patient's legal representative refuses to sign the consent (or the patient if
             he/she is judged competent)

          -  It is impossible to correctly inform the patient's legal representative

          -  The patient has already has Snoezelen-therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Debuysschere, IDE</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marie Cros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Debuysschere, IDE</last_name>
    <phone>+33.(0)4.66.68.39.70</phone>
    <email>jane.debuysschere@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Nîmes - Centre de Gérontologie de Serre Cavalier</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jane Debuysschere, IDE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie Cros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie Crot</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Snoezelen</keyword>
  <keyword>Multi-sensorial care session</keyword>
  <keyword>Alzheimer's-type neurodegenerative disease</keyword>
  <keyword>Dementia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
